Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate CancerBusiness Wire • 09/28/25
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025Business Wire • 09/24/25
Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingBusiness Wire • 09/09/25
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness Wire • 08/29/25
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate CancerBusiness Wire • 08/27/25
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer TestBusiness Wire • 08/26/25
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?Zacks Investment Research • 07/16/25
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025Business Wire • 07/08/25
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer ResearchBusiness Wire • 05/28/25
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin UpZacks Investment Research • 05/09/25